Pamela Stachler, APRN
Psychiatric/Mental Health, Child & Adolescent · Danville, INNPI 1194028696
Payments from drug & device makers
Across 823 payments — averaging $14.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Supernus Pharmaceuticals, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$614
- Ironshore Pharmaceuticals Inc.$606
- Corium, LLC$590
- plus $6K from 25 others
What the payments were for
- Food & beverage$11,89098%
- Education$1872%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 133 | $1,805 |
| Supernus Pharmaceuticals, Inc. | 160 | $1,747 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 54 | $1,062 |
| Teva Pharmaceuticals USA, Inc. | 29 | $614 |
| Ironshore Pharmaceuticals Inc. | 51 | $606 |
| Corium, LLC | 33 | $590 |
| Neos Therapeutics, LP | 47 | $577 |
| Otsuka America Pharmaceutical, Inc. | 32 | $561 |
| Lundbeck LLC | 31 | $540 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $502 |
| Johnson & Johnson(2 entities) | 29 | $486 |
| Alkermes, Inc. | 19 | $352 |
| Neurocrine Biosciences, Inc. | 18 | $352 |
| Noven Therapeutics, LLC | 21 | $351 |
| Tris Pharma Inc | 31 | $346 |
| Vanda Pharmaceuticals Inc. | 16 | $300 |
| Bausch Health US, LLC | 25 | $276 |
| Axsome Therapeutics, Inc. | 12 | $275 |
| Eisai Inc. | 14 | $150 |
| Novo Nordisk | 3 | $140 |
| Adlon Therapeutics L.p. | 6 | $92 |
| Idorsia Pharmaceuticals US Inc | 6 | $90 |
| Sunovion Pharmaceuticals Inc. | 5 | $85 |
| Alfasigma USA, Inc. | 3 | $43 |
| Harmony Biosciences LLC | 1 | $39 |
| Aytu Biopharma, Inc. | 3 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Almatica Pharma LLC | 1 | $17 |
| Brainsway USA Inc | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few psychiatric/mental health, child & adolescent providers in Indianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 23 | $31,238 |
| RexultiBrexpiprazole | 17 | $29,959 |
| BelsomraSuvorexant | 12 | $5,469 |
| Lisdexamfetamine Dimesylate | 15 | $4,171 |
| Vilazodone Hcl | 14 | $2,190 |
| Duloxetine Hcl | 71 | $2,107 |
| Bupropion XlBupropion Hcl | 90 | $1,806 |
| Gabapentin | 21 | $1,661 |
| Atomoxetine Hcl | 13 | $1,528 |
| Ziprasidone Hcl | 23 | $1,428 |
| Aripiprazole | 34 | $1,382 |
| Buspirone Hcl | 51 | $1,242 |
| Olanzapine | 48 | $1,107 |
| Pindolol | 13 | $857 |
| Hydroxyzine Hcl | 22 | $763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,805 | $31,23823 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $561 | $29,95917 claims |
| Lilly USA, LLCOlanzapine | $17 | $1,10748 claims |
| Almatica Pharma LLCSertraline Hcl | $17 | $17748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, child & adolescent providers in Indianaon file to place this against a meaningful peer group, so we don't.
Other psychiatric/mental health, child & adolescent in Danville
- Steven WilsonAnderson$6K
- Susan KerseyLafayette$2K
- Bonnie FryeShelbyville$2K
- Joyce BriggsGreenwood$464
- Brenda Costello WellsIndianapolis$422
- Laura HawkinsLafayette$357
- Yolanda BrayColumbus$330
- Mary BalleBloomington$131
- Charlotte HannahRichmond$87
- Ukamaka OrucheIndianapolis$47
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.